These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

709 related items for PubMed ID: 26157126

  • 1. The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.
    Seay K, Khajoueinejad N, Zheng JH, Kiser P, Ochsenbauer C, Kappes JC, Herold B, Goldstein H.
    J Virol; 2015 Sep; 89(18):9559-70. PubMed ID: 26157126
    [Abstract] [Full Text] [Related]

  • 2. Antiviral and immunological effects of tenofovir microbicide in vaginal herpes simplex virus 2 infection.
    Vibholm L, Reinert LS, Søgaard OS, Paludan SR, Østergaard L, Tolstrup M, Melchjorsen J.
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1404-11. PubMed ID: 22867119
    [Abstract] [Full Text] [Related]

  • 3. Mice transgenic for CD4-specific human CD4, CCR5 and cyclin T1 expression: a new model for investigating HIV-1 transmission and treatment efficacy.
    Seay K, Qi X, Zheng JH, Zhang C, Chen K, Dutta M, Deneroff K, Ochsenbauer C, Kappes JC, Littman DR, Goldstein H.
    PLoS One; 2013 Nov; 8(5):e63537. PubMed ID: 23691059
    [Abstract] [Full Text] [Related]

  • 4. Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings From the VOICE Trial.
    Marrazzo JM, Rabe L, Kelly C, Richardson B, Deal C, Schwartz JL, Chirenje ZM, Piper J, Morrow RA, Hendrix CW, Marzinke MA, Hillier SL, VOICE Study Team.
    J Infect Dis; 2019 May 24; 219(12):1940-1947. PubMed ID: 30753642
    [Abstract] [Full Text] [Related]

  • 5. Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety.
    Nixon B, Jandl T, Teller RS, Taneva E, Wang Y, Nagaraja U, Kiser PF, Herold BC.
    Antimicrob Agents Chemother; 2014 May 24; 58(2):1153-60. PubMed ID: 24323471
    [Abstract] [Full Text] [Related]

  • 6. Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial.
    Bender Ignacio RA, Perti T, Magaret AS, Rajagopal S, Stevens CE, Huang ML, Selke S, Johnston C, Marrazzo J, Wald A.
    J Infect Dis; 2015 Dec 15; 212(12):1949-56. PubMed ID: 26044291
    [Abstract] [Full Text] [Related]

  • 7. Genital herpes simplex virus type 2 infection in humanized HIV-transgenic mice triggers HIV shedding and is associated with greater neurological disease.
    Nixon B, Fakioglu E, Stefanidou M, Wang Y, Dutta M, Goldstein H, Herold BC.
    J Infect Dis; 2014 Feb 15; 209(4):510-22. PubMed ID: 23990571
    [Abstract] [Full Text] [Related]

  • 8. Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.
    Destache CJ, Mandal S, Yuan Z, Kang G, Date AA, Lu W, Shibata A, Pham R, Bruck P, Rezich M, Zhou Y, Vivekanandan R, Fletcher CV, Li Q.
    Antimicrob Agents Chemother; 2016 Jun 15; 60(6):3633-9. PubMed ID: 27044548
    [Abstract] [Full Text] [Related]

  • 9. Novel Role for Interleukin-17 in Enhancing Type 1 Helper T Cell Immunity in the Female Genital Tract following Mucosal Herpes Simplex Virus 2 Vaccination.
    Bagri P, Anipindi VC, Nguyen PV, Vitali D, Stämpfli MR, Kaushic C.
    J Virol; 2017 Dec 01; 91(23):. PubMed ID: 28956763
    [Abstract] [Full Text] [Related]

  • 10. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
    Taneva E, Crooker K, Park SH, Su JT, Ott A, Cheshenko N, Szleifer I, Kiser PF, Frank B, Mesquita PM, Herold BC.
    Antimicrob Agents Chemother; 2015 Dec 28; 60(3):1667-75. PubMed ID: 26711762
    [Abstract] [Full Text] [Related]

  • 11. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, Thomas KK, Fife KH, Nakku-Joloba E, Mujugira A, Baeten JM, Partners PrEP Study Team.
    Ann Intern Med; 2014 Jul 01; 161(1):11-9. PubMed ID: 24979446
    [Abstract] [Full Text] [Related]

  • 12. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2.
    Parr MB, Kepple L, McDermott MR, Drew MD, Bozzola JJ, Parr EL.
    Lab Invest; 1994 Mar 01; 70(3):369-80. PubMed ID: 8145530
    [Abstract] [Full Text] [Related]

  • 13. High-Throughput Humanized Mouse Models for Evaluation of HIV-1 Therapeutics and Pathogenesis.
    Thomas T, Seay K, Zheng JH, Zhang C, Ochsenbauer C, Kappes JC, Goldstein H.
    Methods Mol Biol; 2016 Mar 01; 1354():221-35. PubMed ID: 26714715
    [Abstract] [Full Text] [Related]

  • 14. Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.
    Shankar GN, Alt C.
    J Antimicrob Chemother; 2014 Dec 01; 69(12):3282-93. PubMed ID: 25139839
    [Abstract] [Full Text] [Related]

  • 15. Herpes simplex virus type 2-infected dendritic cells produce TNF-α, which enhances CCR5 expression and stimulates HIV production from adjacent infected cells.
    Marsden V, Donaghy H, Bertram KM, Harman AN, Nasr N, Keoshkerian E, Merten S, Lloyd AR, Cunningham AL.
    J Immunol; 2015 May 01; 194(9):4438-45. PubMed ID: 25840914
    [Abstract] [Full Text] [Related]

  • 16. A sustained type I IFN-neutrophil-IL-18 axis drives pathology during mucosal viral infection.
    Lebratti T, Lim YS, Cofie A, Andhey P, Jiang X, Scott J, Fabbrizi MR, Ozantürk AN, Pham C, Clemens R, Artyomov M, Dinauer M, Shin H.
    Elife; 2021 May 28; 10():. PubMed ID: 34047696
    [Abstract] [Full Text] [Related]

  • 17. IL-36γ induces a transient HSV-2 resistant environment that protects against genital disease and pathogenesis.
    Gardner JK, Herbst-Kralovetz MM.
    Cytokine; 2018 Nov 28; 111():63-71. PubMed ID: 30118914
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic prime/pull vaccination of HSV-2-infected guinea pigs with the ribonucleotide reductase 2 (RR2) protein and CXCL11 chemokine boosts antiviral local tissue-resident and effector memory CD4+ and CD8+ T cells and protects against recurrent genital herpes.
    Quadiri A, Prakash S, Dhanushkodi NR, Singer M, Zayou L, Shaik AM, Sun M, Suzer B, Lau LSL, Chilukurri A, Vahed H, Schaefer H, BenMohamed L.
    J Virol; 2024 May 14; 98(5):e0159623. PubMed ID: 38587378
    [Abstract] [Full Text] [Related]

  • 19. A combination microbicide gel protects macaques against vaginal simian human immunodeficiency virus-reverse transcriptase infection, but only partially reduces herpes simplex virus-2 infection after a single high-dose cochallenge.
    Hsu M, Aravantinou M, Menon R, Seidor S, Goldman D, Kenney J, Derby N, Gettie A, Blanchard J, Piatak M, Lifson JD, Fernández-Romero JA, Zydowsky TM, Robbiani M.
    AIDS Res Hum Retroviruses; 2014 Feb 14; 30(2):174-83. PubMed ID: 24117013
    [Abstract] [Full Text] [Related]

  • 20. Protection against genital herpes infection in mice immunized under different hormonal conditions correlates with induction of vagina-associated lymphoid tissue.
    Gillgrass AE, Tang VA, Towarnicki KM, Rosenthal KL, Kaushic C.
    J Virol; 2005 Mar 14; 79(5):3117-26. PubMed ID: 15709031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.